M1FG
SRPT icon

Mach-1 Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

Mach-1 Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,144
Closed -$496K – 199
2023
Q4 		$496K Buy
+5,144
New +$493K 0.19% 108
2022
Q1 		– Sell
-7
Closed – – 300
2021
Q4 		$0 Buy
+7
New +$598 ﹤0.01% 291

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mach-1 Financial Group's SRPT Position: Q1 2024 in Review

Mach-1 Financial Group sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 5,144 shares — an estimated $496K sold.

Mach-1 Financial Group first reported a position in SRPT in Q4 2021 and held it in 2 quarters. The position peaked at $496K in Q4 2023. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Mach-1 Financial Group reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Mach-1 Financial Group sold 5,144 Sarepta Therapeutics shares in Q1 2024, an estimated $496K.
  • Mach-1 Financial Group first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 2 quarters.
  • Mach-1 Financial Group's Sarepta Therapeutics position peaked at $496K in Q4 2023.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Mach-1 Financial Group's 13F filing for Q1 2024, filed 10 May 2024.